IQV vs. TAK: IQVIA vs. Takeda Pharmaceutical Stock Comparison

Company Profile

IQVIA (IQV) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while TAK is classified in Pharmaceuticals.

IQVIA (IQV) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. IQVIA (IQV) has a non-negative beta of 1.14.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

IQVIA (IQV) at 21.39% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for IQV.

IQVIA (IQV) at 8.05% retains a top-quartile share of revenue as profit, ahead of Takeda Pharmaceutical (TAK) at 0.87%, which keeps about the industry-typical share.

Takeda Pharmaceutical (TAK) at 24.55% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.

Profitability Metrics

Growth

IQVIA (IQV) at 5.87% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while IQVIA (IQV) at 4.67% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Both IQVIA (IQV) at 0.83 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but IQV is more stretched: Takeda Pharmaceutical (TAK) at 0.72 sits in the higher-leverage quartile and IQVIA (IQV) at 2.40 is above its industry benchmark range.

Financial Strength Metrics

Dividends

IQVIA (IQV) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; IQVIA (IQV) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

IQVIA (IQV) at 33.07 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Both IQVIA (IQV) at 2.59 and Takeda Pharmaceutical (TAK) at 0.01 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

Takeda Pharmaceutical (TAK) at 1.43 looks cheap against book in the lower P/B ratio quartile, while IQVIA (IQV) at 6.73 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics